Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is This Blue-Chip Dividend Stock a Buy?


Numerous worries about the state of the global economy and geopolitical climate have led the S&P 500 index to dip 18% so far this year. 

But not all stocks have fared poorly in 2022. In particular, healthcare stocks have held up quite well so far. And shares of one of the most dominant pharmaceutical stocks, Bristol Myers Squibb (NYSE: BMY), have soared 29% higher in 2022. 

After such a run, is the stock a buy for dividend growth investors? Let's dive into Bristol Myers' fundamentals and valuation to address this question.

Continue reading


Source Fool.com

Like: 0
BMY
Share

Comments